Abrdn PLC Neurocrine Biosciences Inc Transaction History

Abrdn PLC

$57.3 Billion
Q2 2025

A detailed history of Abrdn PLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Abrdn PLC holds 118,286 shares of NBIX stock, worth $17.6 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

118,286

Previous 220,344 46.32%

Holding current value

$17.6 Million

Previous $24.4 Million 38.99%

% of portfolio

0.03%

Previous 0.05%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 24, 2025	SELL	$87.54 - $128.18 $8.93 Million - $13.1 Million	-102,058 Reduced 46.32%	118,286 $14.9 Million
Q1 2025 May 13, 2025	BUY	$107.22 - $153.29 $6.84 Million - $9.78 Million	63,770 Added 40.73%	220,344 $24.4 Million
Q4 2024 Jan 24, 2025	BUY	$111.62 - $139.44 $2.25 Million - $2.81 Million	20,150 Added 14.77%	156,574 $21.4 Million
Q3 2024 Oct 24, 2024	SELL	$114.58 - $153.15 $2.83 Million - $3.79 Million	-24,723 Reduced 15.34%	136,424 $15.7 Million
Q2 2024 Aug 09, 2024	BUY	$130.86 - $143.19 $10.2 Million - $11.2 Million	77,935 Added 93.66%	161,147 $22.2 Million
Q1 2024 May 08, 2024	SELL	$130.4 - $143.74 $54,898 - $60,514	-421 Reduced 0.5%	83,212 $11.5 Million
Q4 2023 Jan 31, 2024	BUY	$106.07 - $132.76 $8.53 Million - $10.7 Million	80,420 Added 2502.96%	83,633 $11 Million
Q3 2023 Nov 06, 2023	SELL	$94.02 - $117.1 $25,291 - $31,499	-269 Reduced 7.73%	3,213 $361,000
Q2 2023 Jun 20, 2024	BUY	$89.53 - $104.87 $134,653 - $157,724	1,504 Added 76.04%	3,482 $328,000
Q2 2023 Aug 04, 2023	BUY	$89.53 - $104.87 $134,653 - $157,724	1,504 Added 76.04%	3,482 $328,000
Q1 2023 Jun 20, 2024	SELL	$94.11 - $123.02 $7.64 Million - $9.99 Million	-81,234 Reduced 97.62%	1,978 $200,000
Q1 2023 Apr 28, 2023	BUY	$94.11 - $123.02 $186,149 - $243,333	1,978 New	1,978 $200,000
Q2 2021 Aug 10, 2021	SELL	$89.43 - $102.27 $305,761 - $349,661	-3,419 Closed	0 $0
Q1 2021 May 06, 2021	BUY	$87.57 - $119.4 $22,330 - $30,447	255 Added 8.06%	3,419 $333,000
Q4 2020 Feb 10, 2021	BUY	$86.91 - $108.33 $30,070 - $37,482	346 Added 12.28%	3,164 $303,000
Q3 2020 Oct 21, 2020	SELL	$96.16 - $135.15 $219,533 - $308,547	-2,283 Reduced 44.76%	2,818 $271,000
Q2 2020 Aug 10, 2020	SELL	$85.09 - $130.36 $6.51 Million - $9.97 Million	-76,461 Reduced 93.75%	5,101 $622,000
Q1 2020 May 13, 2020	SELL	$75.11 - $113.76 $52,201 - $79,063	-695 Reduced 0.84%	81,562 $7.06 Million
Q4 2019 Feb 18, 2020	BUY	$86.8 - $118.57 $136,189 - $186,036	1,569 Added 1.94%	82,257 $8.84 Million
Q3 2019 Nov 13, 2019	SELL	$83.82 - $101.5 $1.64 Million - $1.99 Million	-19,608 Reduced 19.55%	80,688 $7.27 Million
Q2 2019 Aug 13, 2019	SELL	$72.24 - $91.27 $340,900 - $430,703	-4,719 Reduced 4.49%	100,296 $8.47 Million
Q1 2019 May 14, 2019	SELL	$69.31 - $91.53 $385,710 - $509,364	-5,565 Reduced 5.03%	105,015 $9.25 Million
Q4 2018 Feb 12, 2019	SELL	$68.32 - $124.36 $1.78 Million - $3.25 Million	-26,127 Reduced 19.11%	110,580 $7.82 Million
Q3 2018 Nov 13, 2018	BUY	$98.88 - $125.85 $13.5 Million - $17.2 Million	136,707 New	136,707 $16.8 Million

Others Institutions Holding NBIX

# of Institutions

667

Shares Held

102M

Call Options Held

290K

Put Options Held

214K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Abrdn PLC, based on Form 13F filings with the SEC.

News

Stay updated on Abrdn PLC with notifications on news.

Account